News from jazz pharmaceuticals plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

17 Jun, 2019, 13:00 BST Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol)

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Drug Enforcement Agency (DEA) has designated solriamfetol, also known as...


03 Jun, 2019, 13:00 BST Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Robert Iannone, M.D., M.S.C.E., as executive vice president, research and...


16 May, 2019, 21:30 BST Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that it will present data from across its hematology/oncology portfolio and pipeline at the...


09 May, 2019, 13:00 BST Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that 14 abstracts sponsored by Jazz Pharmaceuticals and one abstract from an...


06 May, 2019, 21:05 BST Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor...


23 Apr, 2019, 21:05 BST Jazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 first quarter financial results on Tuesday, May 7, 2019, after...


26 Mar, 2019, 20:28 GMT Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the global, double-blind, placebo-controlled,...


05 Mar, 2019, 21:05 GMT Jazz Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Cowen and Company 39th...


26 Feb, 2019, 21:05 GMT Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2018 Financial Results

Total Revenues Increased 17% to $1.9 Billion in 2018 GAAP Diluted EPS of $7.30; Adjusted Diluted EPS of $13.70 Launched Vyxeos for AML in the EU and...


14 Feb, 2019, 21:05 GMT Jazz Pharmaceuticals Announces Appointment of Anne O'Riordan to its Board of Directors

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Anne O'Riordan, Senior Managing Director, Life Sciences of Accenture, was appointed to...


12 Feb, 2019, 21:05 GMT Jazz Pharmaceuticals to Report 2018 Fourth Quarter and Full Year Financial Results on February 26, 2019

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 fourth quarter and full year financial results on Tuesday,...


03 Jan, 2019, 21:05 GMT Jazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes to Create Therapies for Hard-to-Treat Cancers

- Collaboration strengthens Jazz portfolio with novel therapeutic approach that has potential to provide transformational benefit to subgroup of...


21 Dec, 2018, 12:00 GMT Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its new...


19 Dec, 2018, 21:05 GMT Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 7

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 37th Annual J.P. Morgan ...


10 Dec, 2018, 21:10 GMT Jazz Pharmaceuticals Announces Share Repurchase Program Authorization Increase of $400 Million

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its Board of Directors has authorized a $400 million increase in the company's share...


29 Nov, 2018, 13:00 GMT Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 3 clinical trial evaluating the efficacy...


28 Nov, 2018, 13:00 GMT Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2018 Annual Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that nine abstracts, including two oral presentations, relating to the company's...


09 Nov, 2018, 07:00 GMT Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines...


08 Nov, 2018, 00:05 GMT National Institute for Health and Care Excellence (NICE) Recommends Jazz Pharmaceuticals' Vyxeos® (Daunorubicin and Cytarabine) for Adults with Specific Types of Secondary Acute Myeloid Leukaemia (AML)

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Institute for Health and Care Excellence (NICE) has published a Final...


07 Nov, 2018, 21:05 GMT Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at four upcoming investor...


29 Oct, 2018, 12:00 GMT Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved its supplemental new drug...


23 Oct, 2018, 21:05 BST Jazz Pharmaceuticals to Report 2018 Third Quarter Financial Results on November 6, 2018

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 third quarter financial results on Tuesday, November 6, 2018,...


11 Sep, 2018, 21:05 BST Jazz Pharmaceuticals Announces an Informational Webcast for Investors Related to Vyxeos EU Launch

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast to provide investors with an overview of the AML...